Clinical observation of dupilumab in the treatment of 30 adult cases with atopic dermatitis
Objective To evaluate the clinical efficacy and impact on quality of life of dupilumab in adults with moderate-to-severe atopic dermatitis(AD).Methods This study enrolled 30 adult patients with moderate-to-severe AD who received dupilumab treatment for a minimum of 12 weeks at Beijing Chuiyangliu Hospital's dermatology department,from July 2021 to November 2022.The treatment outcomes were assessed by investigator's global assessment(IGA),eczema area and severity index(EASI),scoring atopic dermatitis(SCORAD),peak pruritus numerical rating scale(NRS),patient oriented eczema measure(POEM),dermatology life quality index(DLQI),and atopic dermatitis control test(ADCT).Results 30 adults with moderate-to-severe AD were included in the study.IGA decreased by 1 point in 96.7％of cases,and IGA≤2 points accounted for 76.7％of cases;EASI50 was achieved in 90％of cases,and EASI75 in 80％of cases;NRS decline ≥ 3 points was observed in 100％of cases,and NRS≤4 points in 73.3％of cases.DLQI decline≥4 points accounted for 90％of cases,and DLQI ≤ 5 points accounted for 53.3％.POEM decline ≥ 4 points was observed in 96.7％of cases,and POEM ≤ 7 points accounted for 63.3％;ADCT decline ≥ 5 points accounted for 96.7％of cases,and ADCT ≤ 7 points accounted for 83.3％.Two cases of adverse reactions were observed in this study.One case developed ocular conjunctivitis and blepharitis,which improved after discontinuation of dupilumab treatment and subsequent ophthalmic treatment.The other case experienced depigmentation on the trunk and limbs,with significant improvement observed after a 6-month period.Conclusion The efficacy of dupriuzumab in the treatment of adults with moderate-to-severe AD is significant,accompanied by minimal adverse reactions,leading to a notable improvement in patients'quality of life.
NETL
NSTL
万方数据
